For M&A investors, 2021 will be a year to remember. How will 2022 stack up? As we head into the new year, Harris Williams Industry Group Heads share their views on which trends will drive growth, key investor considerations, and the opportunities to be found in each of the industries we cover. We look forward to pursuing these opportunities in partnership with our clients in the months to come.
How do you feel about M&A conditions heading into 2022 within your industry?
They should be very similar to 2021. There is still a large amount of liquidity in the marketplace, and the underlying conditions driving this market’s strength haven’t changed. As long as there’s plenty of inexpensive money in the system, we believe current M&A conditions will persist. Even if economic conditions degrade, the fundamentals of healthcare will remain robust, and it will continue to be attractive to investors.
Name a few of the most significant trends that will drive growth in your industry in 2022.
In general, healthcare is undergoing “consumerization.” Patients are demanding easier, more modern care delivery aligned with the rest of the services they consume. This typically involves digitization and lessons borrowed from retail, which creates opportunities for investors with relevant experience. In fact, we’re increasingly approaching these opportunities in partnership with our Consumer Group.
Within pharma services, we are seeing significant investment in drugs, biologics, and new genetic therapies. Mental health remains a focus area as well—the pandemic has been hard on people coping with emotional and behavioral issues, and we’re seeing strong investment in providers achieving better outcomes for those patients.
Overall, demand for healthcare products and services is only going to increase for years to come, creating a steady flow of opportunities for investors.
How has your team delivered exceptional client service in this busy market?
We haven’t shifted the fundamentals of how we partner with clients, but we have made adjustments to provide the same quality levels at a much faster pace and on a more virtual basis. We have invested in our team, and we’ve implemented checks and balances to make sure we’re delivering work we feel proud of.
The Harris Williams Healthcare & Life Sciences Group has experience across a broad range of sectors, including healthcare providers; payors and payor services; outsourced pharmaceutical services; medical device supply chain; healthcare IT; and pharmacy. For more information on the HCLS Group and other recent transactions, visit the HCLS Group’s section of the Harris Williams website.
To learn more, please contact our senior bankers.